Table 2.
Treatment groups in antitumor study of ONCOS-102 and pembrolizumab.
| Administration of |
||||
|---|---|---|---|---|
| ONCOS-102 (2.5 × 106 VP/tumor) |
||||
| Group | Left | Right | Pembrolizumab (i.v.) per mouse |
Mode and Days of administration |
| I (Vehicle) |
-(PBS) | -(PBS) | -(PBS) | Days 15, 17, 19 intratumoral i.v. on days 15, 17, 19 and every 3–4 days throughout study |
| II (ONCOS-102) |
+ | + | - | Days 15, 17, 19 intratumoral |
| III (Pembro 200 µg) |
- | - | 200 µg | i.v. on days 15, 17, 19 and every 3–4 days throughout study |
| IV (Pembro 400 µg) |
- | - | 400 µg | i.v. on days 15, 17, 19 and every 3–4 days throughout study |
| V (ONCOS-102 + Pembro 200 µg) |
+ | + | 200 µg | OV: Days 15, 17, 19 intratumoral Pembrolizumab: i.v. on days 15, 17, 19 and every 3–4 days throughout study |
| VI (ONCOS-102 + Pembro 400 µg) |
+ | + | 400 µg | OV: Days 15, 17, 19 intratumoral Pembrolizumab: i.v. on days 15, 17, 19 and every 3–4 days throughout study |
| VII (ONCOS-102 Right flank + Pembro 200 µg) |
- | + | 200 µg | OV: Days 15, 17, 19 intratumoral Pembrolizumab: i.v. on days 15, 17, 19 and every 3–4 days throughout study |
| VIII (ONCOS-102 Right flank + Pembro 400 µg) |
- | + | 400 µg | OV: Days 15, 17, 19 intratumoral Pembrolizumab: i.v. on days 15, 17, 19 and every 3–4 days throughout study |
Eight mice per group in groups I – VI; six mice/group in groups VII and VIII. Abbreviations: OV: oncolytic virus, ONCOS-102